Cancer Therapy Decision Needs More Time, Medicare Chief Says

May 29, 2019

Medicare’s delayed decision on whether to cover a breakthrough cancer therapy reflects the program’s inexperience with cutting-edge medications and the enormous financial pressure that a wave of costly new gene therapy drugs will place on the financially troubled program.